

SUB
C3
B1
CONT.

exposed so as to achieve in said mammal expression of said nucleic acid sequence as permitted in the presence or absence of [said drug] tetracycline or an analog thereof.

SUB
C4
B2

4. (Amended) The method of claim 1, wherein prior to said introducing step, said mammal has made an immune response to said [immunogenic] polypeptide.

5. (Amended) The method of claim 1, wherein prior to said introducing step, said mammal has circulating antibodies which react with said [immunogenic] polypeptide.

6. (Amended) The method of claim 1, wherein prior to said introducing step, said mammal has immunocompetent memory cells which are specific for said [immunogenic] polypeptide.

7. (Amended) The method of claim 1, wherein prior to introduction of the cell into the mammal the expression of the [immunogenic] polypeptide is [substantially] inhibited *in vitro*, and wherein, after introduction of the cell into the mammal, expression of the [immunogenic] polypeptide reaches a maximum level in the mammal after [a delay interval] 2 days.

SUB
C5

8. (Twice amended) The method of claim 7, wherein expression of the [immunogenic] polypeptide is inhibited *in vitro* by exposure of the cell to [the regulatory drug] tetracycline or an analog thereof, and wherein expression in the mammal is induced after [a delay interval] 2 days following removal of [regulatory drug] exposure to tetracycline or an analog thereof.

9. (Twice Amended) The method of claim 7, wherein expression of the [immunogenic] polypeptide is inhibited *in vitro* by [substantial] the absence of [the regulatory drug] tetracycline or an analog thereof and wherein expression in the mammal is induced after [a delay interval] 2 days by administration of [the regulatory drug] tetracycline or an analog thereof to the mammal.

B3
SUB
C6

13. (Amended) The method of claim 1, wherein [the nucleic acid sequence encodes a replicable viral genome or] said vector is a viral vector.

14. (Twice amended) An isolated cell transformed with a nucleic acid sequence encoding a polypeptide which is immunogenic to a mammal, the nucleic acid sequence being operably linked to a [drug] tetracycline-regulatable promoter, such that expression of the immunogenic